See more : PHYZ Holdings Inc. (9325.T) Income Statement Analysis – Financial Results
Complete financial analysis of Australis Capital Inc. (AUSAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Australis Capital Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Equatorial Maranhão Distribuidora de Energia S.A. (EQMA3B.SA) Income Statement Analysis – Financial Results
- CA Immobilien Anlagen AG (CAI.VI) Income Statement Analysis – Financial Results
- Visagar Polytex Limited (VIVIDHA.NS) Income Statement Analysis – Financial Results
- R J BIO-TECH LTD (RJBIOTECH.BO) Income Statement Analysis – Financial Results
- Technofab Engineering Limited (TECHNOFAB.NS) Income Statement Analysis – Financial Results
Australis Capital Inc. (AUSAF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.ausa-corp.com
About Australis Capital Inc.
Australis Capital Inc. operates as a cannabis company. It undertakes cannabis, as well as horticulture projects in the United States, Canada, Denmark Finland, Iceland, Germany, the Netherlands, Bahrein, the United Arab Emirates, Southeast Asia, and Australia, as well as other jurisdictions. The company is based in Las Vegas, Nevada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 7.57M | 570.59K | 221.48K | 129.76K | 0.00 | 0.00 |
| Cost of Revenue | 3.61M | 1.21M | 221.26K | 2.34K | 0.00 | 0.00 |
| Gross Profit | 3.97M | -635.54K | 222.00 | 127.42K | 0.00 | 0.00 |
| Gross Profit Ratio | 52.39% | -111.38% | 0.10% | 98.20% | 0.00% | 0.00% |
| Research & Development | 0.00 | 119.90 | 19.03 | -28.26 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 13.24M | 13.65M | 4.00M | 1.04K | 5.34K |
| Selling & Marketing | 0.00 | 393.20 | 369.35K | 432.94 | 0.00 | 0.00 |
| SG&A | 23.55M | 13.24M | 14.02M | 4.00M | 1.04K | 5.34K |
| Other Expenses | 1.70M | -8.84M | 1.73M | 1.09M | 1.72K | -33.88K |
| Operating Expenses | 25.25M | 8.84M | 14.62M | 4.01M | 1.04K | 5.50K |
| Cost & Expenses | 28.86M | 10.05M | 14.62M | 4.01M | 1.04K | 5.50K |
| Interest Income | 0.00 | 106.77K | 936.76K | 279.71K | 47.16K | 45.02 |
| Interest Expense | 0.00 | 125.22K | 196.56K | 455.69K | 90.54K | 0.00 |
| Depreciation & Amortization | 1.36M | 10.05M | 13.01M | 588.19K | 71.04K | 68.80K |
| EBITDA | -14.13M | -8.87M | -12.25M | -3.01M | 47.85K | -45.18K |
| EBITDA Ratio | -186.60% | -1,553.86% | -5,532.55% | -2,317.99% | 0.00% | 0.00% |
| Operating Income | -15.49M | -9.48M | -14.40M | -4.29M | -1.04K | -5.34K |
| Operating Income Ratio | -204.57% | -1,661.15% | -6,500.66% | -3,309.51% | 0.00% | 0.00% |
| Total Other Income/Expenses | -25.40M | -5.36M | -8.94M | 1.55M | -41.66K | 1.33K |
| Income Before Tax | -40.89M | -19.39M | -23.34M | -4.17M | -42.70K | -4.00K |
| Income Before Tax Ratio | -540.02% | -3,398.90% | -10,539.07% | -3,214.58% | 0.00% | 0.00% |
| Income Tax Expense | 247.44K | -62.18K | 802.74K | 1.04M | 43.38K | -4.00K |
| Net Income | -40.03M | -20.10M | -23.34M | -4.17M | -42.70K | -37.88K |
| Net Income Ratio | -528.67% | -3,522.40% | -10,539.07% | -3,214.58% | 0.00% | 0.00% |
| EPS | -0.16 | -0.11 | -0.14 | -0.04 | 0.00 | 0.00 |
| EPS Diluted | -0.16 | -0.11 | -0.14 | -0.04 | 0.00 | -37.88K |
| Weighted Avg Shares Out | 247.49M | 177.12M | 162.36M | 94.37M | 119.99M | 0.00 |
| Weighted Avg Shares Out (Dil) | 247.49M | 177.12M | 162.36M | 94.37M | 119.99M | 0.00 |
Australis Capital issues corporate update highlighting strong FY 2021 revenue thanks to ALPS, plus New York legalization hopes
Australis Capital Inc (CSE:AUSA) (OTC:AUSAF) has released a corporate update, revealing that its revenue for the fiscal year ended March 31, 2021, is expected to have doubled year-over-year, as well as highlighting a batch of other recent news developments. A big...
Australis Capital issues corporate update highlighting strong FY 2021 revenue thanks to ALPS, plus New York legalisation hopes
Australis Capital Inc (CSE:AUSA) (OTC:AUSAF) has released a corporate update, revealing that its revenue for the fiscal year ended March 31, 2021, is expected to have doubled year-over-year, as well as highlighting a batch of other recent news developments. A big...
Australis Capital, Copperstate Farms Ink $6M Deal To Modernize, Expand Cannabis Cultivation Operations In Arizona
Copperstate Farms, Arizona's largest cannabis wholesaler, is rapidly expanding its facilities to meet customer demand. This week, the company signed a deal worth up to $6 million with ALPS, a subsidiary of Australis Capital Inc (OTC:AUSAF), to significantly upgrade its...
Australis Capital to Webcast Live at VirtualInvestorConferences.com April 20th
LAS VEGAS, April 19, 2021 /PRNewswire/ -- Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) ("AUSA" or the "Company), an innovation driven multi state operator headquartered in Nevada, focused on the global cannabis industry, today announced that Jon Paul, the Company's CFO,...
Australis Capital Inc and Copperstate Farms strike a major facility agreement
Australis Capital Inc (CSE:AUSA) (OTCMKTS:AUSAF) (FRA:AC4) announced that through its majority-owned subsidiary ALPS, it has struck an agreement with Arizona's largest cannabis wholesaler, Copperstate Farms Management LLC for expanded capacity and expanded product lines. Copperstate Farms operates a 40-acre, 1.7...
Australis finds its first chief science officer in University of Alberta lead cardiologist Jason Dyck
Australis Capital Inc (CSE:AUSA) (OTC:AUSAF) (FRA:AC4) has appointed Jason Dyck, director of the Cardiovascular Research Centre at the University of Alberta, as its new chief science officer and chairman of its scientific advisory board, the company announced. Dyck has a...
Wall Street starts in the red
10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX) presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therapeutics Inc (NASDAQ:KTRA) says interim Phase 2 study data on VAL-083 shows its potential as...
Australis Capital completes first phase of Green Therapeutics acquisition with cannabis subsidiary purchase
Australis Capital Inc (CSE:AUSA) (OTC:AUSAF) (FRA:AC4) announced Wednesday that it has completed the first stage of its previously announced acquisition of Nevada cannabis company Green Therapeutics LLC (GT), by purchasing one of its subsidiaries. The subsidiary contains a number of...
Australis' Accretive Acquisitions (Podcast Transcript)
Australis Capital CFO Jon Paul joins the show to discuss closing its acquisitions and why coming on board was a bet on CEO Terry Booth. How MSOs will rationalize over time; optimism on banking opening up.
Australis' Accretive Acquisitions (Podcast)
Australis' Accretive Acquisitions (Podcast)
Source: https://incomestatements.info
Category: Stock Reports